TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06646926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body tempering
Description: Participant will be positioned prone on the Body Tempering Ab Mat with their feet hanging off the end of the mat. The body tempering intervention will be applied by the same investigator for all trials. The body tempering device will be applied dynamically to each participant for 4 minutes, with the device placed on both participants' lower extremities at the same time. First, the examiner will set a timer for two minutes and begin rolling one 80-pound body tempering device along the participant's gastrocnemius-soleus complex at a rate of 30 beats per minute, traveling from the Achilles tendon (medial malleolus) to the inferior aspect of the popliteal fossa, indicated by fibular head. The participant will then take thirty seconds to transition to a supine position and receive tempering with an 80-pound tempering device along their middle to distal quadriceps, set a timer for 2 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam rolling self-myofascial release
Description: Participants will be instructed via standardized script to perform self-myofascial release (SMR) on their gastrocnemius-soleus complex and quadriceps muscles. The first SMR sequence will be performed by having the participant place the foam roller behind both calves, beginning the roll at the medial malleolus and ending at the inferior aspect of the popliteal fossa, indicated by the fibular head. The participant will perform this for two minutes, rolling at a tempo of 30 beats per minute. Next, the participant will take thirty seconds to transition to a prone position, placing the foam roller just distal to the hip crease, just inferior to the AIIS, and rolling inferiorly to the area just proximal to the most superior aspect of the patella. This self-release sequence will be performed for two minutes at a tempo of 30 beats per minute. The total time should be four minutes, matching the total time of the experimental intervention group.
Study: NCT05587712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
Study: NCT05125276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No aspirin
Description: No aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 75-100 mg once daily
Study: NCT05692115

Intervention type: DIAGNOSTIC_TEST
Intervention: stress ECG
Description: stress ECG to patients suspected to be ischemic patients .
Study: NCT05569005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS use
Description: Subjects who are not willing to quit smoking during the study duration will switch from cigarettes to using THS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Subjects who are not willing to quit smoking during the study duration will continue smoking their own preferred brand of commercially available cigarettes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence
Description: Subjects who are willing to quit smoking may be prescribed an NRT to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
Study: NCT06001268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Counseling
Description: Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants will take a survey at baseline and weeks 4,8,\& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Participants will take a survey at baseline and weeks 4,8,\& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
Study: NCT05543915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
Study: NCT05011266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: 5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo sub-lingual tablet daily
Study: NCT04777838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bite Splint
Description: Night use of occlusal splint
Study: NCT06023524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture and Standard Medication
Description: Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture and Standard Medication
Description: Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
Study: NCT04702854

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Biomicroscopy
Description: Measure of cutaneous melanomas by ultrasound Biomicroscopy
Study: NCT06169631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gen0b
Description: The ultrasound will be administered to the brain region of interest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gen0b
Description: The ultrasound will be administered to the brain region of interest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gen0b
Description: The ultrasound will be administered to the brain region of interest.
Study: NCT06518902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells (umbilical cord) injection
Description: Patients receive mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks
Study: NCT05799183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects will receive treatment SHR-1210 before process changes 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects will receive treatment SHR-1210 before process changes 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects will receive treatment SHR-1210 after process changes 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects will receive treatment SHR-1210 after process changes 20 mg
Study: NCT03942211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
Study: NCT05499728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)
Description: Postoperative physical therapy performed through online video conferencing with a licensed physical therapist while the patient remains remote/at home rather than in person
Study: NCT04817995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST
Description: Intervention is going to take the form of an internet-based stress recovery intervention consisting of six modules. The themes include introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These themes were chosen after considering topics that might be the most useful for healthcare staff experiencing high levels of stress. Each module consists of psychoeducation and exercise parts. Psychologist provide individual feedback on completed exercises as well as can be reached on demand.
Study: NCT05736913

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ID BNT162b2 vaccine
Description: intradermal BNT162b2 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IM BNT162b2 vaccine
Description: intramuscular BNT162b2 vaccine
Study: NCT06467058

Intervention type: DEVICE
Group type: OTHER
Intervention: DABQ questionnaire versus Actigraph as reference method
Description: In this study, participants will have one contact session with the researcher, which will be held either at Ghent University Hospital or at the participants' home. During this session, participants will be provided with an accelerometer device and two questionnaires (to be filled in after wearing the Actigraph), namely the Daily Activity Behavior Questionnaire (DABQ) and general information questionnaire.~The participants will receive an Actigraph wGT3X+BT accelerometer which will be worn for seven consecutive days. Instructions will be given on how to wear the accelerometer (e.g. during the day at the hip and during the night at the wrist). At the end of this week, the participants will fill in both questionnaires. After wearing the accelerometer for seven consecutive days and filling in both questionnaires, the researcher will visit the participants to collect the devices, or the participants will send them back by postal package.
Study: NCT05122143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril
Study: NCT04707716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conometric concept Acuris system
Description: implant crown retention type using friction only
Study: NCT05456438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention 1
Description: Group 1 applied coconut oil to the nipple

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention 1
Description: Group 1 applied coconut oil to the nipple
Study: NCT04707716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: screw retention
Description: screw retained implant crown
Study: NCT05456438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention 2
Description: Group 2 applied tea tree oil to the nipple
Study: NCT05223335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 60 mg bolus then 10 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricagrelor
Description: 180 mg bolus then 90 mg twice daily
Study: NCT05554523

Intervention type: DEVICE
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging

Intervention type: DEVICE
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging

Intervention type: DEVICE
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging

Intervention type: DEVICE
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging

Intervention type: DEVICE
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging

Intervention type: DEVICE
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging

Intervention type: DEVICE
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging
Study: NCT05574114

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bridging radiotherapy (BRT)
Description: RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning chemotherapy
Description: Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell product
Description: Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
Study: NCT06147453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobika OPEP device
Description: 16 week twice daily use of the Aerobika OPEP device
Study: NCT04707716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cementation
Description: cement retained implant crown
Study: NCT05995171

Intervention type: OTHER
Intervention: Questionnaire
Description: Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL

Intervention type: OTHER
Intervention: Questionnaire
Description: Quality of life questionnaires will be used specifically for this research: Pediatric Quality of Life Invertory and EA-QoL
Study: NCT04662034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMIC
Description: The C-MIC System consists of three implantable parts: a transvenous and an epicardial lead which are both connected to an implanted power source, and an external programing device. The patch lead is placed over the free wall of the left ventricle and fixated with sutures. When lead placement is achieved, the leads are then tunneled subcutaneously to the infraclavicular region and connected to the power source.
Study: NCT05475613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Downstaging procedures containing immunotherapy
Description: Anti-PD-1 inhibitor will be given every 3-4 weeks intravenously according to the manufacturer's instruction. Other combination regimens, such as locoregional therapies or targeted therapies will be given to patients according to the protocol decided by the multidisciplinary team of Centers.
Study: NCT05122143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril
Study: NCT05475613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Patients with successful downstaging therapy at the end of the observation phase will enroll and undergo liver transplantation unless major medical or oncological contraindications should occur during the waiting phase.
Study: NCT06281678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
Study: NCT04662034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
Study: NCT05122143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~Two Sprays of AM-301 per nostril (with different spray angles)
Study: NCT05412121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.~In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention.
Study: NCT05456022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one
Description: Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying \< 4 % _ Purity (HPLC) \> 95 %

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)
Description: Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
Study: NCT06301399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy
Description: Rituximab: Dissolve 375mg/m2 in 0.9% sodium chloride injection, dilute to a concentration of 1 mg/mL of rituximab, intravenous infusion every 3 weeks until tumor progression or intolerable toxic reactions occur. The recommended initial infusion rate is 50mg/h; After the initial 60 minutes, an increase of 50mg/h can be made every 30 minutes until the maximum speed is 400mg/h. The starting rate of rituximab infusion in the future can be 100mg/h, increasing by 100mg/h every 30 minutes until the maximum rate is 400mg/h.
Study: NCT05604235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic upper limb strength exercise treatment
Description: A treatment with therapeutic strength exercises, twice a week, for two months, with a total of 10 exercises, with 20 repetitions each, aimed at improving the strength of the trapezius and sternocleidomastoid muscles mainly, as well as improving mobility in flexion, abduction and rotation of the affected upper limb. It will take approximately 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with passive and active mobilization of the upper limb.
Description: A treatment with passive kinesitherapy, where the physiotherapist will perform the movements of flexion, abduction and rotation of the shoulder, without the patient's intervention; active kinesitherapy, where the patient will perform specifically prescribed movements, without weight, to improve the articular and muscular balance of the scapulo-humeral complex and neurodynamics, where mobilizations of the accessory spinal nerve will be performed through therapeutic exercise and manual neurodynamic therapy. This treatment will be carried out once a week for two months in 30-minute sessions.
Study: NCT06339983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Scar Mobilization Therapy:
Description: In this therapy, deep pressure on some point of the area of the scar will be given which will be perpendicular to the skin and will be followed by skin rolling
Study: NCT04974528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afrezza
Description: Pharmaceutical form: powder~Route of administration: inhalation
Study: NCT06523595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for Oral Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets for Oral Administration.
Study: NCT05624255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ophthalmologic consultation
Description: Complete ophthalmologic examination including angio-OCT
Study: NCT06635226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID110521156
Description: ID110521156 capsules taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID110521156
Description: ID110521156 capsules taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID110521156
Description: ID110521156 capsules taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of 110521156
Description: ID110521156 placebo capsules taken orally once daily
Study: NCT04974528

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rapid-acting Insulin Analog
Description: Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT06635226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of 110521156
Description: ID110521156 placebo capsules taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of 110521156
Description: ID110521156 placebo capsules taken orally once daily
Study: NCT05328115

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALZ-101
Description: Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALZ-101
Description: Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALZ-101
Description: Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.
Study: NCT06339983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Cupping Therapy:
Description: A disposable plastic cup (5cm) will be positioned at THE selected area of the cesarean scar. Then, negative pressure will be applied using a mechanical vacuum pump, the cup will be gently slid around the selected area rhythmically to get a massage-like effect